EyePoint Pharmaceuticals, Inc.EYPTNASDAQ
LOADING
|||
Switch Symbol:
Net Income Growth Accelerating
Trending higher, above historical average, slight contraction.
Left:
||||
Year-over-year net income growth rate
Latest
-0.51%
↑ 100% above average
Average (39q)
-211.29%
Historical baseline
Range
High:99.06%
Low:-7571.64%
CAGR
-5.7%
Structural decline
| Period | Value |
|---|---|
| Q3 2025 | -0.51% |
| Q2 2025 | -31.49% |
| Q1 2025 | -9.17% |
| Q4 2024 | -41.00% |
| Q3 2024 | 4.75% |
| Q2 2024 | -5.27% |
| Q1 2024 | -107.70% |
| Q4 2023 | -11.79% |
| Q3 2023 | 44.97% |
| Q2 2023 | -8.30% |
| Q1 2023 | 51.29% |
| Q4 2022 | -135.90% |
| Q3 2022 | 5.08% |
| Q2 2022 | 7.48% |
| Q1 2022 | -7.95% |
| Q4 2021 | -16.39% |
| Q3 2021 | -66.78% |
| Q2 2021 | 18.49% |
| Q1 2021 | 20.62% |
| Q4 2020 | -306.97% |
| Q3 2020 | 70.65% |
| Q2 2020 | 1.70% |
| Q1 2020 | -26.55% |
| Q4 2019 | 33.47% |
| Q3 2019 | -36.08% |
| Q2 2019 | 40.23% |
| Q1 2019 | -65.93% |
| Q4 2018 | 65.00% |
| Q3 2018 | 3.78% |
| Q2 2018 | -393.38% |
| Q1 2018 | -20.68% |
| Q4 2017 | 3.36% |
| Q3 2017 | 2.17% |
| Q2 2017 | -18.99% |
| Q1 2017 | -7571.64% |
| Q4 2016 | 99.06% |
| Q3 2016 | -12.13% |
| Q2 2016 | -26.70% |
| Q1 2016 | 2.80% |
| Q4 2015 | -5.13% |